About Inpharmatica
Inpharmatica is a Healthcare company based in London (United Kingdom) founded in 1998, and was acquired by Galapagos in December 2006. Developer of predictive informatics based platform for drug discovery. The company has 62 employees. Its chief executive, as recorded, is John Lisle. Inpharmatica offers products and services including Chemogenomics, Druggability, and Silico. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Discovery. Its legal entity is GALAPAGOS BIOTECH LIMITED.
Company details
Inpharmatica has developed a platform that uses predictive informatics in medicinal chemistry and ADME for drug discovery. The Chemagenomics platform is used for in silico target selection through drug assessment and identification of leads. The company also offers another platform called Silico used for ADME optimization, in silicon and in vitro assessments for identifying leads from hits.
- Headquarters London, United Kingdom
- Employees 62
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website inpharmatica.co.uk
- Acquired by Galapagos (Dec 2006)
- Legal Name Galapagos Biotech Limited
- Date of Incorporation 08 Jul, 1997
- Jurisdiction CAMBRIDGE, CAMBRIDGESHIRE
Products & Services of Inpharmatica
Inpharmatica offers a comprehensive portfolio of products and services, including Chemogenomics, Druggability, and Silico.
Proprietary approach for identifying drug targets and libraries.
Assesses targets for lead chemistry potential in drug discovery.
Tools for early compound selection and property balancing.
Funding Insights of Inpharmatica
- Total Rounds 4
- Last Round Post-IPO — $21.16M
- First Round $6M
(Jun 1998)
- Investors Count 7
All 4 funding rounds of Inpharmatica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $21.16M | Post-IPO | – | – | – |
| Nov 2004 | $25M | Post-IPO | – | – | |
| Jul 2001 | $44M | Post-IPO | – | – | |
| Jun 1998 | $6M | Post-IPO | – | – |
8 investors in total: 8 institutional.
Investors in Inpharmatica
Inpharmatica has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include GLPG, 3i Group and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early to late-stage tech investments are made globally by REV. | rev.vc | London, United Kingdom | ||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Early and mid-stage life science focused VC firm investing in the US and Europe | adventls.com | London, United Kingdom | ||
Private equity and accelerator investments are directed toward multiple sectors. | riveancapital.com | Brussels, Belgium | ||
Early-stage investments are focused on Southeast Asia and India. | vertexventures.com | Palo Alto, United States | ||
Small molecule drugs for immunology and oncology are developed. | 1999 | glpg.com | Mechelen, Belgium |
Investor details for Inpharmatica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Inpharmatica
8 people are tracked at Inpharmatica (8 in leadership); the tracked headcount is 62.
| Name | Role | Group |
|---|---|---|
Patrick John Banks | Executive Director | Leadership |
Xavier Marie Bernard Cecile Maes | Executive Director | Leadership |
Maria Zenarosa Nichol | Executive Director | Leadership |
Walid Michael Abi-saab | Executive Director | Leadership |
David Ross Smith | Executive Director | Leadership |
John Lisle | CEO | Leadership |
Bart Filius | Executive Director | Leadership |
Sean Michael Hird | Executive Director | Leadership |
Complete people profiles for Inpharmatica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Inpharmatica
4 dated milestones of Inpharmatica across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Inpharmatica is founded.
- Funding First funding round of $6.0M.
- Exit Acquired by Galapagos.
- Funding Latest funding round, Post-IPO, of $21.2M.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Inpharmatica (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Inpharmatica
Complete news archive for Inpharmatica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inpharmatica
Inpharmatica was founded in 1998.
Inpharmatica is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.
John Lisle is the CEO of Inpharmatica, as recorded in our data.
Inpharmatica has 62 employees.
Inpharmatica has developed a platform that uses predictive informatics in medicinal chemistry and ADME for drug discovery. The Chemagenomics platform is used for in silico target selection through drug assessment and identification of leads. The company also offers another platform called Silico used for ADME optimization, in silicon and in vitro assessments for identifying leads from hits.
Inpharmatica offers Chemogenomics, Druggability, and Silico.
Inpharmatica has 8 investors. Key investors include GLPG, 3i Group, Gimv, Abingworth, and REV.
Inpharmatica operates through Galapagos Biotech Limited.
Yes. Inpharmatica was acquired by Galapagos in December 2006.